Short answer
Intellia Therapeutics, Inc. (NTLA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results and business updates announced for quarter ended September 30, 2026.
Intellia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results and business updates announced for quarter ended September 30, 2026
- Full results and operating developments available in Exhibit 99.1, the investor-relevant source for detailed figures and outlook
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 results support a potential 2027 commercial inflection, with lonvo-z BLA priority review and March 10, 2027 PDUFA date
- Commercial launch preparation underway, including field organization deployment and payer engagement for a planned first-quarter 2027 launch
- Cash and marketable securities $614.8M, expected to fund operations into 2028, excluding lonvo-z revenue and up to $400M OrbiMed term loan
- MAGNITUDE-2 Phase 3 enrollment completed above 60-patient target, while ATTR-CM enrollment advanced
- Net loss widened to $127.5M from $101.3M, as G&A rose to $46.1M for commercial infrastructure investment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Intellia Therapeutics, Inc. 8-K filings
Get the next NTLA 8-K as it lands
Follow NTLA for push alerts, or ask the research agent what this filing means.